99-9147. Physician Labeling and Patient Labeling for Progestational Drug Products; Warnings and Contraindications

[Federal Register Volume 64, Number 70 (Tuesday, April 13, 1999)]
[Notices]
[Pages 18035-18036]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-9147]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 99N-0486]


Physician Labeling and Patient Labeling for Progestational Drug 
Products; Warnings and Contraindications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that it 
intends to revoke previously issued guidance texts for physician 
labeling and patient labeling for progestational drug products that 
were published in the Federal Register of January 12, 1989 (54 FR 
1243). The reasons for revoking the guidance texts are discussed in a 
notice of proposed rulemaking on progestational drug products that 
appears elsewhere in this issue of the Federal Register.

DATES: Written comments by July 12, 1999.

ADDRESSES: Submit written comments to the Dockets Management Branch 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Diane V. Moore, Center for Drug 
Evaluation and Research (HFD-580), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-4260.


[[Page 18036]]


    Dated: March 25, 1999.
William K. Hubbard,
Acting Deputy Commissioner for Policy.
[FR Doc. 99-9147 Filed 4-12-99; 8:45 am]
BILLING CODE 4160-01-F